Needle-free Self-Injection Pens for Home Vaccinations in Development

PharmaJet today announced the expansion of its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens.

As of October 7, 2025, prototypes of the subcutaneous (SC) injectors, designed for the chronic disease and metabolic peptide self-injection markets, are currently undergoing early testing.

PharmaJet's needle-free injector pens aim to enhance the user experience, alleviate administration anxiety and discomfort, and simplify the injection procedure, particularly for patients with mobility challenges.

Importantly, the reusable PharmaJet injector pens may offer significant advantages over current disposable technologies that generate enormous waste.

"We are excited about the prospect of entering the pen injector market with the PharmaJet needle-free self-injector pens," said Wouter Latour, President and CEO of PharmaJet, in a press release.

"The PharmaJet devices are being designed to provide a superior, user-experience to a wide group of patients, while offering smart e-technology to track dosing and support patient compliance."

"We plan to reach out to industry in the coming months to build partnerships in the exponentially growing metabolic peptide segment and other markets where frequent injections are important."

PharmaJet is a commercial-stage world leader in needle-free injection systems. More than 12 million vaccine injections have been administered worldwide using Tropis®, PharmaJet's intradermal Needle-free Injection System.

Published research comparing Tropis with needle and syringe shows that it is preferred by over 95% of caregivers, and recipients reported reduced pain (68%) and soreness (69%).

PharmaJet's Needle-free Injection Systems deliver a spring-powered injection in 1/10 of a second by means of a narrow stream of fluid that penetrates the skin with a precise dose and depth.

The Stratis System has received U.S. FDA 510(k) marketing clearance, a CE Mark, and WHO PQS certification, enabling the delivery of medications and vaccines via intramuscular or subcutaneous routes. Tropis® ID has CE Mark and WHO PQS certification for intradermal injections and is commercially available for global immunization programs.